• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Interim recommendations for deferral of donors at increased risk for HIV-1 Group O infection; guidance document; availability--FDA. Notice.

出版信息

Fed Regist. 1997 Sep 23;62(184):49695.

PMID:10173802
Abstract

The Food and Drug Administration (FDA) is announcing the availability of a guidance document entitled "Interim Recommendations for Deferral of Donors at Increased Risk for HIV-1 Group O Infection," dated December 11, 1996. The guidance document, which discusses the appearance in 1996 of two cases of HIV-1 Group O infection in the United States, is intended to provide interim measures to reduce the risk of HIV-1 Group O transmission by blood and blood products pending the licensure of test kits specifically labeled for detection of antibodies to HIV-1 Group O viruses. The guidance document recommends adding three questions to screening questionnaires used to exclude donors at high risk of HIV-1 infection.

摘要

相似文献

1
Interim recommendations for deferral of donors at increased risk for HIV-1 Group O infection; guidance document; availability--FDA. Notice.
Fed Regist. 1997 Sep 23;62(184):49695.
2
Revised precautionary measures to reduce the possible transmission of Creutzfeldt-Jakob disease (CJD) by blood and blood products; guidance document; availability--FDA. Notice.修订后的预防措施以减少克雅氏病(CJD)通过血液及血液制品的可能传播;指导文件;可获取性——美国食品药品监督管理局。通知。
Fed Regist. 1997 Sep 23;62(184):49694-5.
3
Guidance for industry: donor screening for antibodies to HTLV-II; availability--FDA. Notice.行业指南:人嗜T淋巴细胞病毒II型抗体供体筛查;可获取性——美国食品药品监督管理局。通知。
Fed Regist. 1998 Sep 29;63(188):51942-3.
4
"Guidance for industry: current good manufacturing practice for blood and blood components: (1). Quarantine and disposition of units from prior collections from donors with repeatedly reactive screening test for antibody to hepatitis C virus (anti-HCV); (2). Supplemental testing, and the notification of consignees and blood recipients of donor test results for anti-HCV;" availability--FDA. Notice.
Fed Regist. 1998 Oct 21;63(203):56198-9.
5
Current good manufacturing practice for blood and blood components; notification of consignees and transfusion recipients receiving blood and blood components at increased risk of transmitting hepatitis C virus infection ("lookback"). Final rule.血液及血液成分现行良好生产规范;向收货人和输血受血者通报接受感染丙型肝炎病毒风险增加的血液及血液成分(“追溯”)。最终规则。
Fed Regist. 2007 Aug 24;72(164):48765-801.
6
Update: HIV-2 infection among blood and plasma donors--United States, June 1992-June 1995.
MMWR Morb Mortal Wkly Rep. 1995 Aug 18;44(32):603-6.
7
FDA seeks temporary blood donor changes. Food and Drug Administration.
AIDS Alert. 1997 Feb;12(2):15-6.
8
Compliance Guidance: The Mammography Quality Standards Act Final Regulations Document #1; availability. Food and Drug Administration, HHS. Notice.合规指南:《乳腺X线摄影质量标准法案》最终法规文件#1;可获取性。美国卫生与公众服务部食品药品监督管理局。通知。
Fed Regist. 1999 Mar 19;64(53):13590-1.
9
Reducing the risk of HIV transmission through blood transfusion by donor self-deferral.通过献血者自我延期来降低输血传播艾滋病毒的风险。
Southeast Asian J Trop Med Public Health. 1996 Sep;27(3):452-6.
10
Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.血液及血液成分现行良好生产规范:向接收有更高感染HIV风险的血液及血液成分的收货人发出通知——美国食品药品监督管理局。最终规则。
Fed Regist. 1996 Sep 9;61(175):47413-23.